Abstract
Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy. Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.
Original language | English (US) |
---|---|
Pages (from-to) | 740-742 |
Number of pages | 3 |
Journal | Cell |
Volume | 171 |
Issue number | 4 |
DOIs | |
State | Published - Nov 2 2017 |
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology